Elos Medtech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Stefano Alfonsi

Chief executive officer

SEK 500.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Stefano Alfonsi (59 yo)

1.3yrs

Tenure

SEK 500,000

Compensation

Mr. Stefano Alfonsi serves as Director at Elos Medtech AB (publ) since December 2021 and serves as CEO & President since September 05, 2022. He served as Chairman at Elos Medtech AB (publ) from May 03, 202...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stefano Alfonsi	CEO, President & Director	1.3yrs	SEK 500.00k	no data
Ewa Linsater	Chief Financial Officer	4.5yrs	no data	0.0071% € 36.4k
Monica Tapper	Chief People Officer	1.8yrs	no data	no data
Soren Olesen	Chief Commercial & Operations Officer Dental	1.9yrs	no data	no data
Tina Friis-Poulsen	Managing Director of Elos Medtech in Gorlose	2.9yrs	no data	no data
Jodie Gilmore	Chief Commercial & Operations Officer Orthopedics	2.9yrs	no data	no data
Conny Jakobsson	Managing Director of Elos Medtech Tianjin Co. Ltd.	1.8yrs	no data	no data
Sam Svännel	Managing Director of Elos Medtech in Timmersdala & Skara	2.1yrs	no data	no data
Tim Turner	Managing Director of Elos Medtech in Memphis	2.9yrs	no data	no data
Mathias Andersson	Chief Executive Officer of Elos Medtech Microplast AB	no data	no data	no data

2.1yrs

Average Tenure

56.5yo

Average Age

Experienced Management: EI9's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stefano Alfonsi	CEO, President & Director	2yrs	SEK 500.00k	no data
Birker Bahnsen	Director	2.3yrs	no data	no data
Lovisa Lander Widengren	Director	2.3yrs	no data	no data
Magnus Rene	Independent Chairman of the Board	1.6yrs	SEK 417.00k	no data
Alexander Cicetti	Director	2.3yrs	no data	no data
Winfried Schaller	Independent Director	less than a year	no data	no data

2.2yrs

Average Tenure

58yo

Average Age

Experienced Board: EI9's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Elos Medtech Management

Management criteria checks 2/4

Key information

Recent management updates

Elos Medtech AB (Publ) Elects Winfried Schaller as Board Member

No independent directors

Elos Medtech AB Announces Nomination Committee Appointments

Elos Medtech AB (Publ) Announces Management Changes

Elos Medtech AB (Publ) Announces Management Changes

Less than half of directors are independent

Recent updates

Elos Medtech AB (publ) (OM:ELOS B) acquired Klingel Holding GmbH from IK Partners and Management.

Elos Medtech Applies for De-Listing from Nasdaq Stockholm

Nasdaq Stockholm Approves Elos Medtech's Application for De-Listing

Elos Medtech Applies for De-Listing from Nasdaq Stockholm

New major risk - Shareholder dilution

Elos Medtech AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Third quarter 2023 earnings released

Investor sentiment deteriorates as stock falls 17%

Elos Medtech AB (publ) (OM:ELOS B) entered an agreement to acquire KLINGEL medical metal GmbH from IK Partners and Management for an enterprise value of €370 million.

New minor risk - Profit margin trend

Second quarter 2023 earnings released

New major risk - Share price stability

Investor sentiment improves as stock rises 20%

Elos Medtech AB (Publ) Elects Winfried Schaller as Board Member

First quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr9.31 (vs kr9.37 in FY 2021)

No independent directors

Elos Medtech AB (publ) to Report Q3, 2023 Results on Oct 19, 2023

Third quarter 2022 earnings released

Elos Medtech AB Announces Nomination Committee Appointments

Elos Medtech AB (Publ) Announces Management Changes

Elos Medtech AB (Publ) Announces Management Changes

Second quarter 2022 earnings released

Investor sentiment improved over the past week

Elos Medtech AB (publ) Omits Dividend for the Year 2021

First quarter 2022 earnings released

Less than half of directors are independent

Investor sentiment improved over the past week

Elos Medtech AB (publ)(OM:ELOS B) dropped from OMX Nordic Small Cap Index

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Independent Director recently sold €83k worth of stock

Second quarter 2021 earnings released: EPS kr2.28 (vs kr0.85 in 2Q 2020)

TA Associates Management, L.P. through its funds Ta Xiii-B, L.P., Ta Xiii-A, L.P. and TA Investors XIII, L.P. made an offer to acquire Elos Medtech AB (publ) (OM:ELOS B) from a group of sellers for SEK 1.7 billion.

Elos Medtech in Talks of Possible Takeover Bid

Investor sentiment improved over the past week

First quarter 2021 earnings released

President & CEO recently sold €79k worth of stock

New 90-day high: €11.95

Revenue misses expectations

Full year 2020 earnings released: EPS kr4.46 (vs kr4.77 in FY 2019)

New 90-day high: €11.50

Elos Medtech AB (publ) Announces Executive Changes

New 90-day high: €11.00

New 90-day high: €9.24

Market bids up stock over the past week

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Elos Medtech AB (publ) to Report Q3, 2021 Results on Oct 20, 2021

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age